Inactive Instrument

Acerus Pharmaceuticals Corporation Toronto S.E.

ASP

CA00444G4051

Rights Issue: 1 new share @ 0.025 CAD for 1.919841 existing shares

October 25, 2020

Latest news about Acerus Pharmaceuticals Corporation

Acerus Pharmaceuticals Brief: Announcing Commencement of Court-Approved Sale and Investment Solicitation Process	23-03-14	MT
Acerus Pharmaceuticals Corporation and its Wholly-Owned Subsidiary, Acerus Pharmaceuticals USA, LLC Enter into USD 2 Million Secured Loan Agreement with First Generation Capital Inc	22-12-22	CI

Chart Acerus Pharmaceuticals Corporation

Duration

Period

Chart Acerus Pharmaceuticals Corporation

More charts

Acerus Pharmaceuticals Corporation is a Canada-based specialty pharmaceutical company. The Company is focused on the commercialization and development of prescription products, with a primary focus in the field of men's health. Its product, Natesto, a testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. Its product pipeline includes Avanafil, Lidbree, and Tefina. Avanafil is a chemical entity, PDE5 inhibitor for the treatment of erectile dysfunction in men. Lidbree, is a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue. It also has product rights to Tefina, a clinical stage product aimed at addressing an unmet need for women with female sexual dysfunction. Its primary market is the United States, where it commercializes its product with its contract commercial provider, Syneos Health (Syneos). It commercializes its products via its own salesforce in the United States and Canada.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Acerus Pharmaceuticals Corporation Toronto S.E.

Equities

ASP

CA00444G4051

Pharmaceuticals

Rights Issue: 1 new share @ 0.025 CAD for 1.919841 existing shares

Latest news about Acerus Pharmaceuticals Corporation

Chart Acerus Pharmaceuticals Corporation

Company Profile

Sector Other Pharmaceuticals